Precision’s PBCAR0191 to Target Autologous CD19 CAR-T Relapsed Patients; PBCAR269A to Be Used with Nirogacestat; ASH 2021 Day 1 Precision Investor Event
On Saturday, December 11, Precision held their investor event (press release / presentation) discussing clinical updates from their CAR-T pipeline at ASH 2021. Celltelligence provides insights on how Precision could leverage the advancement of autologous CD19 CAR-Ts into earlier lines of therapy to target a growing, yet less competitive, patient population.